Transcatheter Mitral-valve Repair Lowers Hospitalization or CV Death vs Medical Therapy Alone in HF with Moderate to Severe MR: RESHAPE-HF2 Trial
Key Points: The Mitral Transcatheter Edge-to-Edge Repair (M-TEER) procedure with the MitraClip device has shown in the previous COAPT trial to reduce heart failure... Read more.
Continuation of Anticoagulation Non-Inferior to Interruption during TAVI: POPular PAUSE TAVI Trial.
Key Points: Many patients who undergo transcatheter aortic-valve implantation (TAVI) have an indication for oral anticoagulation. However, there is uncertainty over... Read more.
Pooled Analysis Showed Semaglutide Reduced Combined CV death or Worsening HF and Worsening HF alone but No Significant Effect on CV Death
Key Points: Heart failure with mildly reduced or preserved ejection fraction (hereafter referred to as HFpEF) is the most common type of heart failure and is associated... Read more.
Transcatheter Edge-To-Edge Repair Is Non-Inferior To Surgery In Patients With Secondary Mitral Regurgitation: MATTERHORN Trial
Key Points: The MATTERHORN trial found that the transcatheter edge-to-edge repair (TEER) procedure was non-inferior to surgical mitral valve repair in reducing functional... Read more.
T-TEER Significantly Reduced the Severity of Secondary Tricuspid Regurgitation and Improved Quality of Life. TRI-FR Trial
Key Points: The TRI.FR trial found that tricuspid transcatheter edge-to-edge repair (T-TEER) together with optimal medical therapy significantly improved the clinical... Read more.
ABYSS – Beta Blocker Interruption in Post-Myocardial Infarction Patients
Key Points: In the ABYSS trial, 3700 patients who had a left ventricular ejection fraction ≥ 40% and were > 6 months post myocardial infarction were randomized... Read more.
Vitrusiran Reduces Risk of Death and CV Events in Patients with ATTR-CM
Key Points: ATTR amyloid cardiomyopathy, resulting from accumulation of TTR amyloid protein in the heart, leads to progressive heart failure, complicated by arrhythmias,... Read more.
Consistent Renal Benefits of Semaglutide in CKD and T2DM Patients With or Without SGLT2 Inhibitors Use. FLOW Trial
The FLOW trial showed that among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), once-weekly subcutaneous semaglutide was superior to placebo... Read more.
Tirzepatide Reduced Apnea-hypopnea Index and Weight in Obese Patients with Moderate Sleep Apnea: SURMOUNT-OSA Trials
Obstructive sleep apnea is associated with cardiovascular complications and is seen more commonly in individuals with excess adiposity. The SURMOUNT OSA phase 3... Read more.
LENS Trial: Fenofibrate Significantly Reduced Progression of Diabetic Retinopathy vs Placebo.
– Findings from cardiovascular trials suggested that fenofibrate therapy may reduce the progression of diabetic retinopathy. – The LENS (Lowering Events... Read more.
